Exploring LBCL: Transplant Eligibility and Second Line Treatment Selection of Novel Agents

Fred Locke, MD, provides an overview of transplant eligibility for patients with large B-cell lymphoma, highlighting second line strategies with CAR T-cell therapy and bispecific antibodies.

Related Keywords

,Transforming Largeb Cell Lymphoma ,Novel Agents ,Transplant Eligibility ,Second Line Treatment Selection ,Dlbcl ,Lymphoma ,Largeb Cell Lymphoma ,Car T ,Cart Cell ,Cart Cell Therapy ,Cart Cell Therapy Lymphoma ,Cart Cell Therapy Largeb Lymphoma ,Patients With Lbcl ,Patients With Largeb Cell Lymphoma ,Mechanisms Of Action ,Clinical Applications ,